• Something wrong with this record ?

Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging

J. Krell-Roesch, JA. Syrjanen, M. Vassilaki, VJ. Lowe, P. Vemuri, MM. Mielke, MM. Machulda, GB. Stokin, TJ. Christianson, WK. Kremers, CR. Jack, DS. Knopman, RC. Petersen, YE. Geda

. 2021 ; 29 (2) : 179-191. [pub] 20200617

Language English Country Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026094

Grant support
K01 MH068351 NIMH NIH HHS - United States
R01 AG041851 NIA NIH HHS - United States
R01 AG056366 NIA NIH HHS - United States
R01 AG034676 NIA NIH HHS - United States
P50 AG016574 NIA NIH HHS - United States
R01 AG011378 NIA NIH HHS - United States
R01 NS097495 NINDS NIH HHS - United States
R01 AG057708 NIA NIH HHS - United States
U01 AG006786 NIA NIH HHS - United States

OBJECTIVE: The authors conducted a prospective cohort study to examine the risk of incident mild cognitive impairment (MCI) as predicted by baseline neuropsychiatric symptoms (NPS) and brain regional glucose metabolic dysfunction. METHODS: About 1,363 cognitively unimpaired individuals (52.8% males) aged ≥50 years were followed for a median of 4.8 years to the outcome of incident MCI. NPS were assessed using Beck Depression and Anxiety Inventories and Neuropsychiatric Inventory Questionnaire. Glucose hypometabolism was measured by fluorodeoxyglucose positron emission tomography and defined as standardized uptake value ratio ≤ 1.47 in regions typically affected in Alzheimer disease. Cox proportional hazards models were adjusted for age, sex, education, and APOE ε4 status. RESULTS: Participants with regional glucose hypometabolism and depression (Beck Depression Inventory-II ≥13) had a more than threefold increased risk of incident MCI (hazard ratio [95% confidence interval], 3.66 [1.75, 7.65], p <0.001, χ2 = 11.83, degree of freedom [df] = 1) as compared to the reference group (normal regional glucose metabolism and no depression), and the risk was also significantly elevated (7.21 [3.54, 14.7], p <0.001, χ2 = 29.68, df = 1) for participants with glucose hypometabolism and anxiety (Beck Anxiety Inventory ≥10). Having glucose hypometabolism and ≥1 NPS (3.74 [2.40, 5.82], p <0.001, χ2 = 34.13, df = 1) or ≥2 NPS (3.89 [2.20, 6.86], p <0.001, χ2 = 21.92, df = 1) increased the risk of incident MCI by more than three times, and having ≥3 NPS increased the risk by more than four times (4.12 [2.03, 8.37], p <0.001, χ2 = 15.39, df = 1). CONCLUSION: Combined presence of NPS with regional glucose hypometabolism is associated with an increased risk of incident MCI, with fluorodeoxyglucose positron emission tomography appearing to be a stronger driving force of cognitive decline than NPS.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026094
003      
CZ-PrNML
005      
20211026133219.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jagp.2020.06.006 $2 doi
035    __
$a (PubMed)32646634
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Krell-Roesch, Janina $u Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, MN; Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany
245    10
$a Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging / $c J. Krell-Roesch, JA. Syrjanen, M. Vassilaki, VJ. Lowe, P. Vemuri, MM. Mielke, MM. Machulda, GB. Stokin, TJ. Christianson, WK. Kremers, CR. Jack, DS. Knopman, RC. Petersen, YE. Geda
520    9_
$a OBJECTIVE: The authors conducted a prospective cohort study to examine the risk of incident mild cognitive impairment (MCI) as predicted by baseline neuropsychiatric symptoms (NPS) and brain regional glucose metabolic dysfunction. METHODS: About 1,363 cognitively unimpaired individuals (52.8% males) aged ≥50 years were followed for a median of 4.8 years to the outcome of incident MCI. NPS were assessed using Beck Depression and Anxiety Inventories and Neuropsychiatric Inventory Questionnaire. Glucose hypometabolism was measured by fluorodeoxyglucose positron emission tomography and defined as standardized uptake value ratio ≤ 1.47 in regions typically affected in Alzheimer disease. Cox proportional hazards models were adjusted for age, sex, education, and APOE ε4 status. RESULTS: Participants with regional glucose hypometabolism and depression (Beck Depression Inventory-II ≥13) had a more than threefold increased risk of incident MCI (hazard ratio [95% confidence interval], 3.66 [1.75, 7.65], p <0.001, χ2 = 11.83, degree of freedom [df] = 1) as compared to the reference group (normal regional glucose metabolism and no depression), and the risk was also significantly elevated (7.21 [3.54, 14.7], p <0.001, χ2 = 29.68, df = 1) for participants with glucose hypometabolism and anxiety (Beck Anxiety Inventory ≥10). Having glucose hypometabolism and ≥1 NPS (3.74 [2.40, 5.82], p <0.001, χ2 = 34.13, df = 1) or ≥2 NPS (3.89 [2.20, 6.86], p <0.001, χ2 = 21.92, df = 1) increased the risk of incident MCI by more than three times, and having ≥3 NPS increased the risk by more than four times (4.12 [2.03, 8.37], p <0.001, χ2 = 15.39, df = 1). CONCLUSION: Combined presence of NPS with regional glucose hypometabolism is associated with an increased risk of incident MCI, with fluorodeoxyglucose positron emission tomography appearing to be a stronger driving force of cognitive decline than NPS.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a stárnutí $x metabolismus $x psychologie $7 D000375
650    _2
$a Alzheimerova nemoc $x metabolismus $7 D000544
650    _2
$a mozek $x diagnostické zobrazování $x metabolismus $7 D001921
650    _2
$a kognitivní dysfunkce $x diagnostické zobrazování $x metabolismus $x patofyziologie $x psychologie $7 D060825
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluorodeoxyglukosa F18 $7 D019788
650    _2
$a glukosa $x metabolismus $7 D005947
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pozitronová emisní tomografie $7 D049268
650    _2
$a prospektivní studie $7 D011446
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Syrjanen, Jeremy A $u Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, MN
700    1_
$a Vassilaki, Maria $u Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, MN
700    1_
$a Lowe, Val J $u Department of Radiology, Mayo Clinic Rochester, Rochester, MN
700    1_
$a Vemuri, Prashanthi $u Department of Radiology, Mayo Clinic Rochester, Rochester, MN
700    1_
$a Mielke, Michelle M $u Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, MN; Department of Neurology, Mayo Clinic Rochester, Rochester, MN
700    1_
$a Machulda, Mary M $u Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, MN; Department of Psychiatry and Psychology, Mayo Clinic Rochester, Rochester, MN
700    1_
$a Stokin, Gorazd B $u International Clinical Research Center/St. Anne Hospital, Brno, Czech Republic
700    1_
$a Christianson, Teresa J $u Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, MN
700    1_
$a Kremers, Walter K $u Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, MN
700    1_
$a Jack, Clifford R $u Department of Radiology, Mayo Clinic Rochester, Rochester, MN
700    1_
$a Knopman, David S $u Department of Neurology, Mayo Clinic Rochester, Rochester, MN
700    1_
$a Petersen, Ronald C $u Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, MN; Department of Neurology, Mayo Clinic Rochester, Rochester, MN
700    1_
$a Geda, Yonas E $u Department of Neurology, Barrow Neurological Institute, Phoenix, AZ. Electronic address: jonasgeda@gmail.com
773    0_
$w MED00008718 $t The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry $x 1545-7214 $g Roč. 29, č. 2 (2021), s. 179-191
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32646634 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133225 $b ABA008
999    __
$a ok $b bmc $g 1714953 $s 1146601
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 29 $c 2 $d 179-191 $e 20200617 $i 1545-7214 $m The American journal of geriatric psychiatry $n Am J Geriatr Psychiatry $x MED00008718
GRA    __
$a K01 MH068351 $p NIMH NIH HHS $2 United States
GRA    __
$a R01 AG041851 $p NIA NIH HHS $2 United States
GRA    __
$a R01 AG056366 $p NIA NIH HHS $2 United States
GRA    __
$a R01 AG034676 $p NIA NIH HHS $2 United States
GRA    __
$a P50 AG016574 $p NIA NIH HHS $2 United States
GRA    __
$a R01 AG011378 $p NIA NIH HHS $2 United States
GRA    __
$a R01 NS097495 $p NINDS NIH HHS $2 United States
GRA    __
$a R01 AG057708 $p NIA NIH HHS $2 United States
GRA    __
$a U01 AG006786 $p NIA NIH HHS $2 United States
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options